Cantor Fitzgerald Reaffirms Overweight Rating for Keros Therapeutics (NASDAQ:KROS)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a research note released on Friday,Benzinga reports.

Other equities research analysts also recently issued research reports about the company. Bank of America cut their price target on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Guggenheim started coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Performance

NASDAQ KROS opened at $56.58 on Friday. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -10.86 and a beta of 1.23. The business has a 50 day simple moving average of $59.32 and a 200 day simple moving average of $52.16. Keros Therapeutics has a 52-week low of $27.31 and a 52-week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm’s revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the business posted ($1.33) earnings per share. On average, analysts predict that Keros Therapeutics will post -5.28 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV grew its holdings in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after acquiring an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. bought a new position in Keros Therapeutics in the 3rd quarter valued at $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the 2nd quarter valued at $128,000. Finally, Ameritas Investment Partners Inc. increased its holdings in Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after buying an additional 324 shares during the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.